Patients' Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer.

ABSTRACT: SCOT was an international, randomized phase 3 trial of 3 months vs 6 months of adjuvant chemotherapy with oxaliplatin and a fluoropyrimidine in patients with colorectal cancer. We sought patients' preferences for 3 months vs 6 months of adjuvant chemotherapy in the SCOT trial. SCOT participants from Australia and New Zealand completed a validated questionnaire (at 3 and 18 months) to elicit the minimum survival benefits judged necessary to make an extra 3 months of adjuvant chemotherapy worthwhile, based on their experience. Standardized hypothetical scenarios used the following baseline survivals (with 3 months of chemotherapy): life expectancies (LE) of 5 years and 15 years and 5-year survival rates (5YS) of 65% and 85%. Of the 160 participants, 82 were assigned 3 months adjuvant chemoth

SUBMITTER: Blinman P 

PROVIDER: S-EPMC7883552 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature